Novabridge Biosciences (NASDAQ:NBP – Get Free Report) insider Mark Arnold Hagler acquired 46,000 shares of the firm’s stock in a transaction dated Tuesday, November 17th. The shares were purchased at an average price of $0.34 per share, with a total value of $15,640.00. Following the completion of the transaction, the insider owned 276,000 shares of the company’s stock, valued at $93,840. This trade represents a 20.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Mark Arnold Hagler also recently made the following trade(s):
- On Wednesday, November 18th, Mark Arnold Hagler purchased 184,000 shares of Novabridge Biosciences stock. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $69,920.00.
Novabridge Biosciences Stock Down 2.6%
Novabridge Biosciences stock traded down $0.02 during trading hours on Thursday, reaching $0.88. 213,480 shares of the company’s stock were exchanged, compared to its average volume of 681,761. The firm’s 50 day simple moving average is $1.27 and its 200 day simple moving average is $1.98. Novabridge Biosciences has a twelve month low of $0.75 and a twelve month high of $5.19. The firm has a market capitalization of $102.06 million, a PE ratio of -2.44 and a beta of 1.70.
Novabridge Biosciences (NASDAQ:NBP – Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. Analysts anticipate that Novabridge Biosciences will post -0.54 EPS for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on NBP shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novabridge Biosciences in a research note on Thursday, August 27th. Wall Street Zen upgraded Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Novabridge Biosciences in a research note on Thursday, August 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $9.00.
Read Our Latest Research Report on Novabridge Biosciences
Novabridge Biosciences Company Profile
Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.
Read More
- Five stocks we like better than Novabridge Biosciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Novabridge Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabridge Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
